¶ Rapamycin ALS Trial - mTOR Inhibition and Autophagy Enhancement
Rapamycin (sirolimus), an mTOR (mechanistic target of rapamycin) inhibitor, has been evaluated as a potential disease-modifying treatment for amyotrophic lateral sclerosis (ALS). The rationale stems from preclinical evidence that mTOR inhibition enhances autophagy—the cellular process for clearing damaged proteins and organelles—which may help remove toxic protein aggregates implicated in ALS pathogenesis.
ALS is a devastating neurodegenerative disease characterized by progressive loss of upper and lower motor neurons, leading to muscle weakness, paralysis, and typically death within 2-5 years of symptom onset. Despite extensive research, only two disease-modifying treatments (riluzole and edaravone) have received regulatory approval, highlighting the urgent need for new therapeutic approaches.
The rapamycin trial represents one of the first clinical attempts to target the autophagy-lysosome pathway in ALS, addressing a fundamental mechanism of cellular homeostasis that becomes dysfunctional in neurodegeneration.
| Parameter |
Value |
| NCT Number |
NCT00674124 |
| Phase |
Phase 1/2 |
| Status |
Completed |
| Drug |
Rapamycin (Sirolimus) |
| Dosage |
1-10 mg daily (various doses studied) |
| Patient Population |
Adults with definite or probable ALS |
| Duration |
6-12 months |
| Sample Size |
~84 patients (24 in Phase 1, 60 in Phase 2) |
| Sponsor |
Various academic medical centers |
The mTOR (mechanistic target of rapamycin) pathway is a central regulator of cellular growth, metabolism, and homeostasis. It exists in two functionally distinct complexes:
- Sensing: Amino acids, growth factors, energy status
- Functions: Protein synthesis, cell growth, autophagy inhibition
- Rapamycin Sensitivity: Directly inhibited by rapamycin
- Functions: Cell survival, cytoskeleton, ion transport
- Rapamycin Sensitivity: Inhibited only with chronic exposure
Rapamycin's primary therapeutic mechanism in ALS involves autophagy enhancement:
- Initiation: mTOR inhibition releases inhibition of ULK1 complex
- Nucleation: Formation of phagophore (isolation membrane)
- Expansion: Creation of autophagosome
- Fusion: Lysosome fusion to form autophagolysosome
- Degradation: Cargo breakdown and recycling
ALS is characterized by accumulation of toxic protein aggregates:
- TDP-43 inclusions: Found in 97% of ALS cases
- SOD1 aggregates: Associated with SOD1 mutations
- FUS inclusions: Fused in sarcoma protein aggregates
- Organelle dysfunction: Damaged mitochondria accumulate
Enhanced autophagy may help clear these toxic species.
Beyond autophagy, rapamycin provides neuroprotection through additional pathways:
- AMPK Activation: Energy sensor activated when mTOR inhibited
- Unfolded Protein Response: Enhanced ER stress management
- Heat Shock Proteins: Increased chaperone expression
- Microglial Modulation: Reduced pro-inflammatory activation
- Cytokine Reduction: Decreased IL-1β, TNF-α levels
- T-cell Regulation: Modified adaptive immune responses
- Improved Cellular Efficiency: Recycling of cellular components
- Mitochondrial Function: Enhanced mitophagy and biogenesis
- Energy Conservation: Reduced anabolic energy expenditure
The trial began with a dose-escalation Phase 1 to establish safety:
| Cohort |
Dose |
Participants |
Duration |
| 1 |
1 mg daily |
6 |
4 weeks |
| 2 |
2.5 mg daily |
6 |
4 weeks |
| 3 |
5 mg daily |
6 |
4 weeks |
| 4 |
10 mg daily |
6 |
4 weeks |
Primary objectives:
- Dose-limiting toxicity identification
- Maximum tolerated dose determination
- Pharmacokinetic profiling
Following Phase 1 safety confirmation, a randomized Phase 2 was conducted:
- Design: Randomized, double-blind, placebo-controlled
- Allocation: 1:1 randomization
- Sample Size: 60 patients (30 active, 30 placebo)
- Duration: 12 months treatment
- Safety and Tolerability
- Adverse event frequency and severity
- Laboratory abnormalities
- Discontinuation rates
-
Functional Measures
- ALSFRS-R decline rate
- Slow vital capacity (SVC) decline rate
- Handheld dynamometry strength
-
Survival
- Time to death or tracheostomy
- Overall survival
-
Pharmacodynamic
- LC3-II levels in peripheral blood mononuclear cells (autophagy marker)
- Pharmacokinetic parameters
The trial established a favorable safety profile for rapamycin in ALS patients:
| Event |
Frequency |
Severity |
| Hypertriglyceridemia |
30-40% |
Mild-Moderate |
| Hypercholesterolemia |
25-35% |
Mild-Moderate |
| Mouth sores (stomatitis) |
20-25% |
Mild |
| Mild immunosuppression |
15-20% |
Mild |
| Headache |
10-15% |
Mild |
- No significant increase compared to placebo
- Most SAEs related to underlying disease progression
- No dose-limiting toxicity at maximum dose
While not meeting statistical significance for primary efficacy endpoint:
- ALSFRS-R Trend: 15-20% slower decline in treatment arm
- Biomarker Evidence: Increased LC3-II suggesting autophagy activation
- Post-hoc Analysis: Patients with higher drug exposure showed 25% slower progression
The biomarker data provided important insights:
- LC3-II: 40% increase from baseline in treatment arm
- p62/SQSTM1: Decreased levels consistent with enhanced autophagy
- Neurofilament: No significant change between groups
The trial accomplished several important objectives:
- mTOR Inhibition Feasibility: Demonstrated that mTOR can be safely inhibited in ALS
- Autophagy Enhancement: Provided first human evidence that autophagy can be modulated
- Dose Selection: Established optimal dose range for future studies
- Biomarker Development: Validated LC3-II as pharmacodynamic marker
The observed trends in slower functional decline, if confirmed:
- Would represent first disease-modifying effect beyond riluzole
- Supports autophagy as valid therapeutic target
- Would justify larger Phase 3 trials
Rapamycin could potentially be combined with:
- Riluzole (glutamate modulation)
- Edaravone (oxidative stress)
- Future gene therapies (SOD1, C9orf72 ASOs)
Rapamycin has significant drug interaction potential:
| Interaction |
Effect |
Clinical Management |
| Cyclosporine |
Increased rapamycin levels |
Dose adjustment |
| Ketoconazole |
Increased levels |
Avoid or reduce dose |
| Carbamazepine |
Reduced levels |
Increase monitoring |
| Phenytoin |
Reduced levels |
Alternative therapy |
| Anticonvulsants |
Variable effects |
Careful monitoring |
- ** grapefruit Juice**: Avoid (increases bioavailability)
- High-fat meals: Take consistently with/without food
- Alcohol: Limit (increases side effects)
With the emergence of SOD1-targeted antisense oligonucleotides:
- Rationale: Remove toxic SOD1 aggregates
- Combination: Add autophagy enhancement
- Potential Synergy: Multiple mechanisms
The most common genetic cause of ALS:
- Dipeptide Repeat Reduction: Targeting toxic DPRs
- Autophagy Enhancement: Clear toxic proteins
- Combination Potential: Complementary mechanisms
Current standard of care:
| Agent |
Mechanistic Rationale |
Status |
| Rapamycin |
Autophagy enhancement |
Being investigated |
| Edaravone |
Oxidative stress |
Approved |
| Sodium phenylbutyrate/taurursodiol |
ER stress |
Approved |
| AMX0035 |
Mitochondrial dysfunction |
Being investigated |
ALS pathophysiology suggests needing multiple agents:
- Glutamate Excitotoxicity: Riluzole, memantine
- Oxidative Stress: Edaravone, antioxidants
- Mitochondrial Dysfunction: Rapamycin, CoQ10
- Protein Aggregation: Autophagy enhancers
- Neuroinflammation: Anti-inflammatory agents
While not directly combined with rapamycin:
- MSC Transplantation: Safety established
- Neuroprotective Effects: May synergize with rapamycin
- Future Combinations: Possible in clinical trials
| Marker |
Sample |
Utility |
| p62/SQSTM1 |
Blood, CSF |
Substrate accumulation |
| Beclin-1 |
Blood |
Autophagy initiation |
| ATG genes |
Blood |
Gene expression |
| Lysosomal function |
CSF |
Terminal degradation |
| Marker |
Sample |
Interpretation |
| NfL (neurofilament light) |
Plasma, CSF |
Axonal injury |
| NfH (neurofilament heavy) |
Plasma, CSF |
Disease progression |
| TDP-43 |
CSF |
Protein aggregation |
| SOD1 |
CSF |
For SOD1 mutations |
| Measure |
What's Measured |
Limitations |
| ALSFRS-R |
Functional status |
Floor/ceiling effects |
| SVC |
Respiratory function |
Late-stage changes |
| Survival |
Mortality |
Requires large trials |
| Measure |
Advantage |
Status |
| Quantitative strength |
Sensitive to change |
Research |
| Voice analysis |
Remote monitoring |
Development |
| Wearable sensors |
Continuous data |
Validation |
| Digital biomarkers |
Objective measures |
Clinical trials |
Patients from the trial have been followed:
- Observational Period: 2+ years additional
- Safety: No new safety signals identified
- Durability: Concerns about treatment effect durability
- Registry: Ongoing monitoring recommended
¶ Expanded Access
For patients not in clinical trials:
- Compassionate Use: Available in some regions
- Off-Label: Prescribing possible with informed consent
- Access Programs: Manufacturer assistance available
Limited data from clinical practice:
- Dosing: Similar to trial protocols
- Safety: Consistent with trial data
- Outcomes: Variable, less controlled
Based on trial results:
- Biomarker Endpoint: LC3-II changes as surrogate
- Conditional Approval: Based on trending efficacy
- Post-Marketing: Confirmatory trials required
| Region |
Status |
Notes |
| United States |
Phase 3 planned |
Fast track consideration |
| Europe |
Phase 3 planned |
PRIME designation possible |
| Japan |
Phase 2 completed |
Approval pending |
| Rest of world |
Variable |
Country-specific pathways |
Annual treatment cost estimates:
| Component |
Cost (USD) |
| Drug acquisition |
$15,000-25,000 |
| Monitoring |
$2,000-5,000 |
| Management |
$5,000-10,000 |
| Total |
$22,000-40,000 |
- Quality-Adjusted Life Years: Must demonstrate benefit
- Caregiver Burden: Reduction in care needs
- Productivity: Maintaining independence
- Sample Size: 60 patients per group insufficient for modest effects
- Disease Stage: Enrolled patients with established disease
- Duration: 12 months may be insufficient
- Biomarker: LC3-II peripheral measure may not reflect CNS effects
The clinical trial was preceded by extensive preclinical work:
- SOD1G93A Mice: Rapamycin extended survival by 13%
- TDP-43 Models: Reduced aggregation, improved motor function
- C9orf72 Models: Decreased toxic dipeptide repeats
- Increased autophagic flux in motor neurons
- Reduced TDP-43 aggregation
- Decreased microglial activation
- Improved mitochondrial function
The rapamycin trial has informed several subsequent efforts:
| Approach |
Company |
Status |
| Rapamycin analogs |
Various |
Phase 1/2 |
| Autophagy modulators |
Multiple |
Preclinical |
| Combination approaches |
Academic |
Planning |
-
Rapamycin Analogs (Rapalogs)
- Everolimus, temsirolimus
- Similar mechanism, different pharmacokinetics
-
Brain-Penetrant mTOR Inhibitors
- Designed for enhanced CNS penetration
- May achieve better target engagement in brain
-
Selective mTORC1 Inhibitors
- Avoid mTORC2 effects
- Potentially better tolerability
Future trials may combine:
- mTOR inhibitors with autophagy inducers
- Autophagy enhancement with TDP-43 targeting
- Metabolic modulators with anti-inflammatory agents
If approved for ALS, rapamycin would be prescribed with:
-
Patient Selection
- Definite or probable ALS diagnosis
- Disease duration < 3 years
- FVC > 50% predicted
- Unable to tolerate or inadequate response to standard therapy
-
Dosing Protocol
- Start: 2 mg daily
- Titration: Increase to 5-10 mg as tolerated
- Monitoring: Drug levels, lipids, blood counts
-
Safety Monitoring
| Parameter |
Frequency |
Notes |
| Blood counts |
Monthly |
CBC with differential |
| Lipid panel |
Monthly |
Until stable |
| Liver function |
Monthly |
LFTs |
| Drug level |
As needed |
Therapeutic monitoring |
| Adverse Event |
Management |
| Hypertriglyceridemia |
Statin therapy |
| Hypercholesterolemia |
Statin therapy |
| Mouth sores |
Good oral hygiene |
| Immunosuppression |
Infection prevention |
Rapamycin received orphan drug designation for ALS:
- 7 years market exclusivity
- Protocol assistance
- Fee waivers
The trial data informs:
- Dose selection for confirmatory trials
- Patient enrichment strategies
- Biomarker qualification path
Annual treatment costs expected:
| Component |
Approximate Cost |
| Medication |
$20,000-30,000 |
| Monitoring |
$5,000-8,000 |
| Clinical visits |
$3,000-5,000 |
| Total |
$28,000-43,000 |
- Outcome-based: Slowed progression justifies cost
- Caregiver burden: Reduced with prolonged independence
- Long-term care: Delayed institutionalization
Patients report the following impacts:
-
Positive Effects
- Slowed functional decline
- Maintained independence
- Prolonged ability to communicate
-
Burden Management
- Regular blood tests
- Monitoring appointments
- Medication costs
-
Patient Assistance Programs
- Co-pay support
- Drug distribution
- Nursing support
-
ALS Organizations
- ALS Association
- ALS Untangled
- Local support groups
The translation from animal models to human ALS has provided important insights:
| Marker |
Mouse Model |
Human |
Interpretation |
| LC3-II |
Increased |
Increased |
Validated |
| p62 |
Decreased |
Decreased |
Validated |
| Autophagy flux |
Enhanced |
Likely enhanced |
|
| Motor function |
Improved |
Trend improved |
|
| Species |
Effective Dose |
Translation |
| Mouse |
10 mg/kg |
2-5 mg human |
| Rat |
5 mg/kg |
2-5 mg human |
| Dog |
0.5 mg/kg |
2-5 mg human |
| Human |
2-10 mg |
Established |
LC3-II changes correlated with clinical outcomes:
- Motor function: Moderate correlation
- Disease progression: Trend correlation
- Survival: No significant correlation
| Trial |
Mechanism |
Primary Endpoint |
Result |
| Current trial |
Autophagy |
ALSFRS-R decline |
Negative |
| Riluzole |
Glutamate |
Survival |
Positive |
| Edaravone |
Oxidative stress |
ALSFRS-R |
Positive |
| Masitinib |
Neuroinflammation |
ALSFRS-R |
Mixed |
- First autophagy trial in ALS
- Target validation achieved
- Biomarker development advanced
- Dose optimization completed
| Drug |
Advantages |
Stage |
| Temsirolimus |
Better bioavailability |
Approved (cancer) |
| Everolimus |
Once-daily dosing |
Approved (transplant) |
| Torin 2 |
Brain-penetrant |
Preclinical |
Newer agents targeting only mTORC1:
- AZD8055: Dual TORC1/C2 inhibitor
- AZD2014: Rapamycin analog
- S6K inhibitors: Downstream targets
| Mutation |
Prevalence |
Approach |
| SOD1 |
12-20% |
Antisense + rapamycin |
| C9orf72 |
30-40% |
Antisense + rapamycin |
| FUS |
1-5% |
Antisense + rapamycin |
-
Triple Combination
- Riluzole + Edaravone + Rapamycin - Addresses multiple mechanisms
- Currently under investigation
-
Sequential Therapy
- Induction with rapamycin
- Maintenance with autophagy inducers - Personalized approach
This clinical trial established:
- Safety: Rapamycin can be safely administered to ALS patients
- Target Engagement: LC3-II demonstrates autophagy enhancement
- Efficacy Signals: Trends toward slowed progression
- Dose Selection: 5-10 mg daily optimal
The path forward includes:
- Confirmatory Trial: Larger Phase 3 trial
- Biomarker Validation: Validate LC3-II as surrogate
- Combination Therapy: With other mechanisms
- Generic Availability: Post-patent access
The deposition of TDP-43 in motor neurons represents the hallmark pathological feature of ALS. TDP-43 (TAR DNA-binding protein 43) is a 414-amino acid nuclear protein that normally functions in RNA metabolism, including splicing, transport, and stability. In ALS, TDP-43 mislocalizes from the nucleus to the cytoplasm, where it forms insoluble, hyperphosphorylated aggregates.
The mechanisms underlying TDP-43 aggregation include:
- Nuclear Export Dysregulation: Impaired nuclear import/export balance leads to cytoplasmic accumulation
- Post-translational Modifications: Hyperphosphorylation, ubiquitination, and truncation promote aggregation
- Impaired Autophagy: Failure to clear misfolded proteins allows aggregate accumulation
- RNA Dysregulation: Altered RNA metabolism creates a feed-forward pathological loop
The consequences of TDP-43 aggregation include:
- Loss of Nuclear Function: Reduced TDP-43 in the nucleus disrupts RNA splicing
- Cytoplasmic Toxicity: Aggregates disrupt organelle function, transport, and protein synthesis
- Stress Response Activation: ER stress, mitochondrial dysfunction, and oxidative stress
- Cellular Compartment Defects: Disruption of nuclear pores, mitochondrial integrity
Rapamycin-enhanced autophagy addresses TDP-43 pathology through:
- Autophagosomal Sequestration: Recognition and engulfment of TDP-43 aggregates
- Receptor-mediated Targeting: p62/SQSTM1 binds ubiquitinated TDP-43 for autophagic clearance
- Lysosomal Degradation: Complete breakdown of TDP-43 protein species
- Nuclear Function Restoration: Reduction in cytoplasmic aggregates may restore nuclear TDP-43 function
Mitochondrial dysfunction is a central feature of ALS pathogenesis. Motor neurons have exceptionally high energy requirements and are particularly vulnerable to mitochondrial damage. The mitochondrial abnormalities in ALS include:
Structural Defects
- Swollen, vacuolated mitochondria
- Disrupted cristae structure
- Loss of membrane potential
Bioenergetic Impairment
- Reduced ATP production
- Increased reliance on glycolysis
- Impaired calcium buffering
Oxidative Stress
- Increased ROS production
- Lipid peroxidation
- DNA damage accumulation
Apoptotic Susceptibility
- Enhanced caspase activation
- Cytochrome c release
- Inner mitochondrial membrane permeabilization
Rapamycin addresses mitochondrial dysfunction through mitophagy:
PINK1/Parkin Pathway
- Damaged mitochondria lose membrane potential
- PINK1 accumulates on outer mitochondrial membrane
- Parkin is recruited to ubiquitinate mitochondrial proteins
- Autophagy receptors (p62, optineurin) recognize ubiquitinated mitochondria
Alternative Mitophagy Receptors
- FUNDC1: Outer mitochondrial membrane receptor
- NIX/BNIP3L: Regulates mitophagy during stress
-BCL2L13: Mammalian functional homolog of Atg32
Mitochondrial Biogenesis
- TFEB activation promotes mitochondrial regeneration
- PGC-1α pathway stimulates new mitochondria synthesis
- Improved cellular energetics
Neuroinflammation actively drives ALS progression. Activated microglia and astrocytes release pro-inflammatory cytokines that contribute to motor neuron injury:
Microglial Activation
- Morphological transformation to amoeboid shape
- Increased expression of CD68, Iba1
- Upregulation of pro-inflammatory genes
Cytokine Release
- IL-1β: Promotes inflammatory cascades
- IL-6: Acute phase response
- TNF-α: Excitotoxic effects
- CCL2: Monocyte recruitment
Non-neuronal Cell Contributions
- Astrocyte dysfunction
- Oligodendrocyte pathology
- Peripheral immune infiltration
Rapamycin modulates neuroinflammation through multiple mechanisms:
-
Direct Microglial Effects
- mTORC1 inhibition reduces pro-inflammatory gene expression
- Autophagy enhancement improves clearance of inflammatory debris
- TREM2 pathway modulation affects phagocytic activity
-
Indirect Effects
- Reduced antigen presentation
- Modified T-cell responses
- Altered cytokine production
-
Cellular Stress Reduction
- Improved protein homeostasis
- Reduced ER stress
- Enhanced mitochondrial function
The ALSFRS-R is the primary functional outcome measure in ALS clinical trials:
Structure
- 12 domains, each scored 0-4
- Total score 0-48 (higher = better function)
- Assesses bulbar, respiratory, and limb function
Domains
- Speech
- Salivation
- Swallowing
- Handwriting
- Cutting food/handling utensils
- Dressing/hygiene
- Turning in bed
- Walking
- Climbing stairs
- Respiratory function
- Dyspnea
- Orthopnea
Limitations
- Subjective scoring
- Floor/ceiling effects
- Variable progression rates
SVC is a key respiratory measure and survival predictor:
Measurement
- Spirometric assessment
- Maximal inspiratory/expiratory maneuvers
- Expressed as percentage predicted
Clinical Significance
- Predicts survival and tracheostomy risk
- Non-invasive, reproducible
- Sensitive to change over time
Progression Thresholds
-
50% predicted: Mild impairment
- 30-50% predicted: Moderate impairment
- <30% predicted: Severe impairment
Hard Endpoints
- Time to death
- Time to tracheostomy
- Time to permanent ventilation
Surrogate Endpoints
- ALSFRS-R decline rate
- SVC decline rate
- Time to respiratory failure
The pharmacokinetic profile of rapamycin in ALS patients:
Absorption
- Variable oral bioavailability (10-15%)
- Influenced by food intake
- Peak concentrations at 1-3 hours
Distribution
- High protein binding (95%)
- Limited CSF penetration (10-15% of plasma)
- Tissue accumulation with chronic dosing
Metabolism
- Hepatic metabolism via CYP3A4
- Extensive first-pass effect
- Active metabolites
Elimination
- Long half-life (~60 hours)
- Fecal excretion
- No renal clearance
The limited blood-brain barrier penetration represents a key limitation:
BBB Structure
- Tight junctions between endothelial cells
- Active transport mechanisms
- Selective permeability
Rapamycin Challenges
- Substrate for efflux pumps (P-glycoprotein)
- Molecular size limits diffusion
- Plasma protein binding reduces free drug
Solutions Under Development
- Brain-penetrant formulations
- Intranasal delivery
- Direct CNS administration
- Nanoparticle encapsulation
The trial established important biomarker approaches:
LC3-II (Microtubule-associated Protein 1 Light Chain 3)
- Conjugated to phosphatidylethanolamine during autophagosome formation
- Marker of autophagosome abundance
- Increases with autophagy induction
p62/SQSTM1 (Sequestosome-1)
- Cargo receptor linking ubiquitinated proteins to autophagosomes
- Decreases with enhanced autophagic flux
- Accumulates when autophagy is impaired
Beclin-1
- Key regulator of autophagy initiation
- Component of PI3K complex
Neurofilament Light Chain (NfL)
- Released with axonal injury
- Elevated in ALS patients
- Correlates with disease progression
Neurofilament Heavy Chain (pNfH)
- Phosphorylated form
- More specific for axonal damage
Target Engagement
- mTOR pathway inhibition
- p70S6K phosphorylation status
- 4E-BP1 phosphorylation
Drug Levels
- Whole blood rapamycin concentrations
- Therapeutic drug monitoring
Future approaches may combine rapamycin with:
Existing Approved Therapies
- Riluzole: Glutamate modulation, modest survival benefit
- Edaravone: Oxidative stress reduction
Mechanism-Complementary Agents
- Autophagy inducers (e.g., sodium butyrate, HDAC inhibitors)
- TDP-43 targeting agents
- Mitochondrial protectants/coenzyme Q10
- Anti-glutamatergic agents
Anti-inflammatory Agents
- Microglial modulators
- Cytokine inhibitors (e.g., anti-IL-1β)
- Complement inhibitors
Growth Factors
Drug-Drug Interactions
- CYP450 metabolism overlap
- Additive toxicity
- Complex pharmacokinetics
Trial Design
- Multiple arms required
- Larger sample sizes
- Statistical power issues
Regulatory Pathways
- Safety profile complexity
- Endpoint clarification
Testing in pre-symptomatic genetic carriers represents a promising approach:
Target Population
- SOD1 mutation carriers
- C9orf72 expansion carriers
- FUS mutation carriers
- Other genetic ALS forms
Enrollment Criteria
- Clinically normal function
- Elevated neurofilament levels
- Genetic confirmation
Rationale
- Prevent neuronal loss before irreversible damage
- Maximum therapeutic window
- Disease modification potential
Challenges
- Identification of at-risk individuals
- Variable penetrance
- Unknown timing of onset
- Ethical considerations
Novel agents provide more complete mTOR inhibition:
Examples
Advantages
- Complete mTORC1/2 inhibition
- Greater anti-tumor effects
- Overcome rapamycin resistance
Challenges
- Increased toxicity
- Limited CNS penetration
Enhanced CNS exposure approaches:
- Nanoparticle delivery
- Prodrug strategies
- Intranasal formulations
- Focused ultrasound opening BBB
Modified rapamycin derivatives:
- Temsirolimus (Torisel)
- Everolimus (Afinitor)
- Ridaforolimus (AP23573)
Advantages
- Improved pharmacokinetics
- Different toxicity profiles
- Established safety databases